How Much Melanotan-2 Per Day? (Daily Dose Guide)

A 2019 study published in the Journal of Clinical and Aesthetic Dermatology found that melanocortin receptor agonists like Melanotan-2 demonstrate dose-dependent melanogenesis. Meaning pigmentation response scales directly with cumulative dose during the first 14–21 days of administration, not with peak single-injection amounts. Most research protocols fail because they skip the loading phase entirely, jumping straight to maintenance dosing without establishing baseline receptor saturation.

Our team has worked with hundreds of research labs navigating peptide titration protocols. The gap between doing it correctly and ending up with inconsistent data comes down to three variables most guides never mention: receptor density timing, cumulative exposure windows, and the interplay between dose frequency and half-life kinetics.

How much Melanotan-2 should be administered per day in research protocols?

Melanotan-2 dosing in research settings typically follows a two-phase protocol: a loading phase of 0.25mg to 0.5mg daily for 7–10 days to establish melanocortin receptor saturation, followed by a maintenance phase of 0.5mg to 1mg administered 2–3 times per week. Total daily exposure during loading rarely exceeds 0.5mg to minimise nausea and flushing, while maintenance dosing focuses on cumulative weekly exposure rather than daily frequency. The protocol is highly variable based on subject baseline pigmentation and research endpoints.

The issue is that 'per day' is a misleading frame for Melanotan-2 protocols. Because the peptide has a plasma half-life of approximately 33 minutes but a biological effect duration measured in days, not hours. Receptor-level melanogenesis doesn't require daily dosing once loading is complete. This article covers the exact titration schedule research labs use, how cumulative dose determines outcomes more than single-injection amounts, and what preparation mistakes compromise data integrity before the first injection.

Understanding Melanotan-2 Mechanism and Dose Response

Melanotan-2 functions as a non-selective melanocortin receptor agonist, binding primarily to MC1R (melanogenesis), MC3R and MC4R (appetite and libido modulation), and MC5R (exocrine function). The pigmentation effect comes from MC1R activation on melanocytes, triggering eumelanin synthesis through the cAMP–MITF–tyrosinase pathway. This is mechanistically different from UV-induced tanning: UV radiation causes DNA damage that upregulates p53, which then stimulates melanin production as a protective response. Melanotan-2 bypasses the UV trigger entirely, activating melanocytes directly through receptor binding.

Dose-response curves published in Peptides (2003) demonstrate that melanogenesis follows a sigmoidal pattern. Minimal response below 0.2mg daily, logarithmic increase between 0.25mg and 1mg, and plateau above 1.5mg where additional dosing yields diminishing pigmentation returns but escalating side effect probability. The threshold for visible pigmentation in fair-skinned subjects (Fitzpatrick Type I–II) is approximately 3–5mg cumulative dose over 7–10 days. For subjects with baseline melanin (Type III–IV), the threshold drops to 2–3mg cumulative.

The critical variable is cumulative exposure within the receptor saturation window, not peak daily dose. A protocol administering 0.5mg daily for 10 days (5mg cumulative) produces comparable pigmentation to 1mg daily for 5 days, but with significantly lower incidence of nausea and facial flushing. Because side effects scale with peak plasma concentration, while efficacy scales with cumulative receptor engagement over time. Research labs designing controlled protocols prioritise steady-state receptor occupancy over high-peak-low-trough dosing patterns.

Titration Protocols: Loading Phase vs Maintenance Dosing

Standard research protocols divide Melanotan-2 administration into two distinct phases with different dosing logic. The loading phase establishes baseline receptor saturation and triggers initial melanogenesis. This requires daily or near-daily dosing at 0.25mg to 0.5mg for 7–14 days depending on subject baseline pigmentation and tolerance to side effects. Subjects with Fitzpatrick Type I skin (very fair, always burns) typically require 10–14 days at the lower end of the range, while Type III–IV subjects may achieve target pigmentation within 7–10 days at 0.5mg daily.

Maintenance dosing shifts to 2–3 administrations per week once visible pigmentation develops, with individual doses ranging from 0.5mg to 1mg depending on the desired pigmentation depth and subject-specific response. The biological rationale: melanin synthesis, once initiated, persists for 48–72 hours after a single Melanotan-2 dose due to sustained elevation of tyrosinase enzyme activity and continued melanocyte proliferation. Daily dosing during maintenance is unnecessary and increases side effect burden without proportional efficacy gains.

Common titration error: starting at 1mg on day one. Melanocortin receptor density in naive subjects is insufficient to handle high initial doses. The result is severe nausea, spontaneous erections (in male subjects due to MC4R activation), and facial flushing lasting 2–4 hours post-injection. These effects diminish significantly with slow upward titration as receptor density adapts. A properly designed protocol starts at 0.25mg, assesses tolerance over 2–3 days, then increases to 0.5mg if no prohibitive side effects occur. Rushing this phase is the single most common cause of protocol abandonment in research settings.

Reconstitution, Storage, and Dose Preparation

Melanotan-2 is supplied as lyophilised powder in 10mg vials, requiring reconstitution with bacteriostatic water before administration. Standard reconstitution uses 2mL bacteriostatic water per 10mg vial, yielding a concentration of 5mg/mL. Meaning each 0.1mL (10 units on a standard insulin syringe) contains 0.5mg of active peptide. This concentration simplifies dosing: 0.25mg = 5 units (0.05mL), 0.5mg = 10 units (0.1mL), 1mg = 20 units (0.2mL).

Storage requirements are strict. Unreconstituted lyophilised Melanotan-2 is stable at −20°C for up to 24 months, or at 2–8°C (standard refrigeration) for 3–6 months. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 30 days. Bacteriostatic water contains 0.9% benzyl alcohol to inhibit bacterial growth, but this only delays degradation, it doesn't prevent it indefinitely. Any temperature excursion above 25°C for more than 4 hours causes irreversible peptide bond hydrolysis, rendering the solution inactive. This is not detectable by visual inspection. Degraded Melanotan-2 looks identical to viable peptide.

Dosing precision matters. Subcutaneous injection technique must deliver the solution into adipose tissue, not intramuscular or intradermal. Injection sites rotate between abdomen, thigh, and upper arm to prevent lipohypertrophy (localised fat buildup from repeated injection trauma). Draw the calculated dose using a 0.5mL or 1mL insulin syringe with 29-gauge or smaller needle. Air bubbles must be expelled before injection. Air introduced into subcutaneous tissue causes localised inflammation and inconsistent absorption kinetics. Our team has found that protocols requiring daily injections benefit from pre-loading weekly doses into individual syringes, stored capped in the refrigerator. This reduces contamination risk and improves dosing consistency.

Melanotan-2 Dosing Protocols: Research Use Comparison

What If: Melanotan-2 Dosing Scenarios

What If a Subject Experiences Severe Nausea During Loading Phase?

Reduce the dose by 50% immediately and hold at that level for 3–5 days before attempting upward titration again. Nausea from Melanotan-2 is mediated by MC4R activation in the hypothalamus and area postrema. It's dose-dependent and typically resolves within 2–3 hours post-injection, but severe cases can last 6–8 hours and include vomiting. Administering the injection in the evening before sleep allows subjects to sleep through peak nausea. If nausea persists beyond day 7 of loading at 0.25mg, the protocol should be paused. Persistent GI symptoms suggest either product contamination or an idiosyncratic melanocortin receptor sensitivity that contraindicates continued use.

What If Reconstituted Melanotan-2 Was Left Out of the Refrigerator Overnight?

If the ambient temperature was below 25°C and exposure was less than 12 hours, the solution is likely still viable but potency may be reduced by 10–20%. If the temperature exceeded 25°C or exposure exceeded 12 hours, discard the vial. Peptide bond hydrolysis is irreversible and there is no reliable at-home method to verify potency. Continuing to use degraded peptide wastes research time and introduces confounding variables. The visible appearance of the solution does not change with degradation. Degraded Melanotan-2 remains clear and colourless, indistinguishable from fresh product.

What If Pigmentation Plateaus After Two Weeks on Maintenance Dosing?

Increase the weekly cumulative dose by 25–50%. Either by adding a third weekly injection or increasing individual dose amounts from 0.5mg to 0.75mg. Pigmentation plateau typically indicates that the maintenance dose is insufficient to sustain melanogenesis above baseline melanin degradation rate, which occurs naturally through keratinocyte turnover every 28–30 days. Some subjects require 3mg weekly cumulative to maintain target pigmentation, particularly those with fair baseline skin and high outdoor UV exposure (which accelerates melanin breakdown). If plateau persists after dose adjustment, consider a second loading phase of 0.5mg daily for 5–7 days to re-saturate receptors.

The Unfiltered Truth About Melanotan-2 Dosing Claims

Here's the honest answer: most online Melanotan-2 dosing guides are written by people who have never designed a controlled peptide protocol. The '1mg daily' recommendation you see repeated across forums and grey-market supplier sites is not based on clinical evidence. It's an arbitrary midpoint between 'too little to work' and 'too much to tolerate' that became standard through repetition, not research. The actual literature shows daily dosing above 0.5mg during loading increases side effect incidence by 40–60% without improving melanogenesis speed or depth.

The mechanism matters: melanocortin receptors don't reset overnight. Once activated, MC1R remains in a state of elevated tyrosinase expression for 48–72 hours. Dosing daily at 1mg during maintenance is physiologically redundant. You're activating receptors that are already active, which increases systemic melanocortin signalling (appetite suppression, libido changes, blood pressure effects) without proportional pigmentation benefit. The optimal protocol is not 'more is better'. It's 'sustained receptor engagement with minimal peak side effects,' which means lower doses at higher frequency during loading, then spaced dosing during maintenance.

The quality of the peptide itself is non-negotiable. Melanotan-2 synthesis requires precise peptide sequencing. The molecule is a cyclic heptapeptide with a disulfide bridge between Cys4 and Cys10, and any error in that cyclisation or oxidation step produces an inactive analogue. Our experience working with researchers shows that at least 30% of grey-market Melanotan-2 fails HPLC purity verification, containing either incorrect peptide sequences, bacterial endotoxin contamination, or insufficient active compound to produce therapeutic effects. If your protocol isn't working after 14 days at proper cumulative doses, the issue is likely product purity. Not dosing strategy.

Melanotan-2 protocols demand attention to procedural detail. The difference between reliable data and wasted resources is whether you counted dose units correctly, stored the reconstituted vial at the right temperature, and understood that 'per day' is the wrong frame for a peptide with multi-day receptor kinetics. If you're designing a protocol, build it around cumulative weekly exposure and receptor saturation windows. Not arbitrary daily amounts copied from unverified sources. Our high-purity research peptides are synthesised with exact amino-acid sequencing to eliminate the guesswork. Because in research, inconsistent results aren't just frustrating, they're unusable.

FAQ

1. How much Melanotan-2 per day should be administered during the initial loading phase? The standard loading dose is 0.25mg to 0.5mg daily for 7–14 days, depending on subject baseline pigmentation and tolerance. Subjects with very fair skin (Fitzpatrick Type I) start at 0.25mg and titrate to 0.5mg after 3–5 days if side effects are minimal. The goal is cumulative exposure of 3–5mg over the loading period, not peak daily amounts.

2. Can Melanotan-2 be dosed once weekly instead of multiple times per week? Once-weekly dosing is insufficient to maintain steady-state melanogenesis during maintenance. The biological effect window of Melanotan-2 is 48–72 hours, meaning receptor activity returns to baseline 3–4 days post-injection. Weekly dosing creates a peak-trough pigmentation cycle rather than sustained melanin synthesis. Minimum effective maintenance frequency is twice weekly.

3. What is the difference between Melanotan-2 and Melanotan-1 (afamelanotide) dosing? Melanotan-1 is a selective MC1R agonist with minimal activity at MC3R and MC4R, resulting in fewer systemic side effects but requiring higher doses for comparable pigmentation. Typically 1mg daily during loading. Melanotan-2 is non-selective, producing pigmentation at lower doses (0.5mg) but with higher incidence of nausea, appetite suppression, and libido changes due to MC4R activation. The peptides are not interchangeable despite similar names.

4. How long does pigmentation last after stopping Melanotan-2? Pigmentation fades gradually over 4–8 weeks as melanin-containing keratinocytes undergo natural turnover and are replaced by cells without elevated melanin content. The rate of fade depends on baseline skin type and UV exposure. Subjects with naturally darker skin retain pigmentation longer than fair-skinned subjects. Residual pigmentation may persist for 3–6 months at levels slightly above pre-treatment baseline.

5. What causes the nausea associated with Melanotan-2, and how can it be minimised? Nausea results from MC4R activation in the hypothalamus and area postrema (the brain's chemoreceptor trigger zone). It is dose-dependent and typically peaks 30–90 minutes post-injection. Mitigation strategies include starting at 0.25mg and titrating slowly, administering injections in the evening before sleep, eating a small meal 1–2 hours before injection, and avoiding alcohol or high-fat foods on injection days. Severe nausea lasting beyond 4 hours or accompanied by vomiting suggests the dose is too high.

6. Can Melanotan-2 be used without UV exposure, or is sunlight required for pigmentation? Melanotan-2 produces pigmentation independent of UV exposure by directly activating MC1R on melanocytes. However, UV exposure accelerates and deepens the pigmentation response through synergistic mechanisms. UV-induced DNA damage upregulates p53, which further stimulates melanin synthesis. Research protocols typically include controlled UV exposure (e.g., 10–15 minutes of midday sun 2–3 times weekly) to maximise melanogenesis, but it is not required for visible pigmentation to occur.

7. What is the appropriate dose adjustment for subjects with darker baseline pigmentation (Fitzpatrick Type IV–VI)? Subjects with darker skin require shorter loading phases (7–10 days vs 10–14 days) and may achieve target pigmentation at lower cumulative doses (2–3mg vs 3–5mg). Maintenance dosing remains comparable at 0.5–1mg per injection 2–3 times weekly. The primary difference is faster onset of visible pigmentation and lower side effect incidence due to higher baseline melanocortin receptor density.

8. How should Melanotan-2 be stored if long-term research requires multi-month supply? Unreconstituted lyophilised Melanotan-2 should be stored at −20°C for optimal long-term stability, where it remains viable for up to 24 months. Refrigeration at 2–8°C is acceptable for 3–6 months but introduces gradual degradation risk. Reconstituted peptide must always be refrigerated and used within 30 days. For multi-month protocols, reconstitute one vial at a time and store the remaining lyophilised powder frozen.

9. What are the signs that reconstituted Melanotan-2 has degraded and is no longer effective? Degraded Melanotan-2 has no reliable visual indicators. The solution remains clear and colourless even after peptide bond hydrolysis. The only detectable sign is loss of efficacy: if pigmentation stalls or reverses despite consistent dosing, or if typical side effects (nausea, flushing) disappear entirely, degradation is likely. This is why strict refrigeration and adherence to the 30-day use window is non-negotiable.

10. Can Melanotan-2 cause permanent pigmentation changes or skin damage? No. Melanotan-2 produces reversible melanogenesis. Once dosing stops, pigmentation fades to baseline over 4–8 weeks as melanin-containing keratinocytes are naturally shed. It does not cause permanent melanocyte hyperplasia or alter baseline melanin production capacity. However, the peptide does not provide meaningful UV protection at research doses, so subjects still require sunscreen to prevent UV-induced photoageing and DNA damage.

11. Is there a threshold dose below which Melanotan-2 produces no pigmentation effect? Yes. Doses below 0.2mg daily during loading rarely produce visible pigmentation within standard research timelines (14–21 days). The threshold for melanogenesis in fair-skinned subjects is approximately 0.25mg daily for at least 7 days, yielding 1.75mg cumulative exposure. Below this threshold, receptor activation is insufficient to upregulate tyrosinase enzyme activity above baseline melanin synthesis rates.

12. How does Melanotan-2 dosing compare to natural melanin production from sun exposure? Melanotan-2 produces pigmentation equivalent to 2–3 weeks of daily moderate sun exposure (20–30 minutes of midday UVB) within 10–14 days of loading, but without UV-induced DNA damage or photoageing effects. The pigmentation depth is comparable but the mechanism is fundamentally different: UV triggers melanin as a damage response, while Melanotan-2 activates melanocytes directly through receptor binding. The peptide does not replace the need for UV protection. It only accelerates melanogenesis independent of sun exposure.

This guide reflects current understanding of melanocortin receptor pharmacology and peptide handling protocols. Dosing decisions, titration schedules, and safety monitoring must be determined by qualified research personnel based on specific experimental endpoints and subject characteristics.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on Melanotan-2 indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-2 for laboratory research use only.

1. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020. PMID 31953620. doi:10.1007/s13730-020-00447-z
2. Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International journal of molecular sciences, 2020. PMID 31968661. doi:10.3390/ijms21020681
3. The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. The Journal of pharmacology and experimental therapeutics, 2007. PMID 17567964. doi:10.1124/jpet.107.123091
4. Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. PMID 12704398. doi:10.1038/sj.ijo.0802280
5. MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiology & behavior, 2003. PMID 12834806. doi:10.1016/s0031-9384(03)00118-5
6. Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain research, 2003. PMID 12834882. doi:10.1016/s0006-8993(03)02683-0